GNCA GENOCEA BIOSCIENCES

Scott+Scott, Attorneys at Law, LLP Filed Class Action Against Genocea Biosciences, Inc. (GNCA) – Lead Plaintiff Deadline is January 2nd

Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, has filed a class action against Genocea Biosciences, Inc. (“Genocea” or the “Company”) (NASDAQ:GNCA) and certain of its senior executives related to alleged violations of federal securities laws. If you purchased or otherwise acquired shares of Genocea common stock between May 5, 2017 and September 25, 2017, you are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for additional information.

Genocea is a biopharmaceutical company that discovers and develops vaccines and immunotherapies. During the Class Period, the Company’s lead product candidate was GEN-003, a genital herpes immunotherapy product.

The lawsuit alleges that the Company and certain executives issued false and misleading statements to investors, including in filings with the U.S. Securities and Exchange Commission (“SEC”). Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s finances were insufficient to support Phase 3 trials of GEN-003; (ii) accordingly, Genocea had overstated the prospects for GEN-003; and (iii) as a result of the foregoing, Genocea’s public statements were materially false and misleading at all relevant times.

On September 25, 2017, after the market closed, Genocea disclosed that it was halting spending and activities on GEN-003 and exploring strategic alternatives for the drug. The Company also announced that it was cutting 40% of its workforce.

On this news, the Company’s share price fell $4.08, or 76.5%, to close at $1.25 on September 26, 2017.

What You Can Do

If you purchased Genocea common stock between May 5, 2017 and September 25, 2017, inclusive, or if you have questions about this notice or your legal rights, please contact attorney Rhiana Swartz at (844) 818-6980, or at [email protected]. Investors have until January 2, 2018, to move for lead plaintiff.

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

EN
12/12/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GENOCEA BIOSCIENCES

 PRESS RELEASE

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

Genocea Announces Wind Down of Operations and Delisting From NASDAQ CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the ...

 PRESS RELEASE

Genocea Initiates Restructuring and Announces Plan to Explore Strategi...

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company,...

 PRESS RELEASE

Genocea Biosciences to Host Investor Webinar

Genocea Biosciences to Host Investor Webinar CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss , including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripher...

 PRESS RELEASE

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conferenc...

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET. A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at . A replay of t...

 PRESS RELEASE

Genocea Provides Fourth Quarter 2021 Corporate Update

Genocea Provides Fourth Quarter 2021 Corporate Update Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021. GEN-011 TiTAN™ trial update Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell (NPT) therapy ca...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch